News

Colesevelam, an orally administered, bile-acid sequestrant showed efficacy in reducing LDL-C lipoproteins and drug-interaction and tolerability profile comparable to placebo. Valeant chairman and CEO Michael Pearson said clinical

The MycoDiverse library is a collection of 10,000 refined fractions from fermentations of higher fungi, developed using the company’s technology to stimulate secondary metabolite production. The collection is

The trial aims to investigate the safety and tolerability of YM’s JAK1/JAK2 inhibitor, as well as its efficacy in reducing spleen size, improving constitutional symptoms and reducing transfusion

The company said there are no therapies for patients with LAL Deficiency. However, SBC-102 can possibly be a disease modifying long-term enzyme replacement therapy for patients including infants,

The two-stage single arm open label study in combination with gemcitabine enrolled nearly 35 patients to study the overall survival rate. The study is said to have met

The contracts for drug development, valued at $56.3m were awarded to Neumedicines, RxBio, the University of Arkansas for Medical Sciences of Little Rock, Araim Pharmaceuticals of Ossining and

As per the terms of the deal, Galderma will acquire substantially all of Graceway’s assets including inventory and intellectual property rights and will assume the majority of Graceway’s

Northera is indicated as a treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy. The NDA

The Phase 1 dose escalation portion of the trial aims to investigate a single injection of different HTI-501 formulations into dimpled lesions of the skin followed by a